N-Desalkylflurazepam is a potent, long-acting benzodiazepine derivative widely studied in the fields of neuropharmacology, forensic toxicology, and receptor-binding research. It is an active metabolite of several clinically known benzodiazepines, such as flurazepam and fludiazepam, but it is not approved for therapeutic use itself. Due to its non-prodrug nature and extremely long half-life, it allows researchers to study sustained central nervous system (CNS) modulation with minimal metabolic interference.

• Directly Active Metabolite
  Unlike many benzodiazepines that rely on hepatic metabolism to become pharmacologically active, N-Desalkylflurazepam is inherently active and does not require conversion. This offers researchers a more stable foundation for evaluating its effects on GABA-A receptors without the variability introduced by metabolic intermediates.

• High Affinity for GABA-A Receptors
  It binds to the benzodiazepine site on GABA-A receptors with high affinity, enhancing the inhibitory neurotransmitter GABA’s effects. This property makes it highly valuable in receptor binding assays and CNS-inhibition modeling.

• Extremely Long Half-Life
  With a biological half-life exceeding 100 hours in some research models, it provides prolonged receptor occupation and sustained behavioral or physiological effects in experimental settings.

• Structurally Simplified
  It lacks the alkyl group present in many parent compounds, which contributes to its metabolic resilience and increased stability during in vitro or in vivo studies.

• Not Intended for Human Consumption
  While derived from compounds used clinically, it is not approved for medical use and is intended strictly for qualified laboratory or forensic research.

The chemical structure of N-Desalkylflurazepam reflects its classification as a 1,4-benzodiazepine. Its unique substituents and lack of an alkyl side chain differentiate it from many parent compounds, giving it specific binding properties and a longer metabolic lifespan.

• Molecular Formula: C15H10ClFN2O
  This formula indicates the presence of a benzodiazepine core with a chlorine atom, a fluorine atom, and a ketone group contributing to its chemical stability.

• Chlorine and Fluorine Substituents
  The inclusion of halogens like chlorine and fluorine improves the molecule’s lipid solubility and enhances its ability to cross the blood-brain barrier in research settings.

• Absence of an N-Alkyl Group
  Most benzodiazepines feature a side-chain alkyl group, which facilitates metabolism. N-Desalkylflurazepam lacks this, making it more metabolically stable and resistant to enzymatic breakdown.

• Aromatic Ring System
  The two fused rings and one diazepine ring define its interaction with CNS receptors, aiding predictability in structure-activity relationship (SAR) studies.

• Ketone Functionality
  The ketone group contributes to its electrophilic character and its ability to participate in hydrogen bonding with receptor sites, influencing binding duration and affinity.

N-Desalkylflurazepam has found a prominent place in several scientific disciplines due to its pharmacological stability, predictable action, and clean profile. Researchers turn to this compound for precise data acquisition in fields requiring consistent benzodiazepine receptor modulation.

• Receptor-Binding Assays
  Its high binding affinity for the GABA-A receptor benzodiazepine site makes it ideal for radioligand binding studies, receptor selectivity assays, and competitive inhibition experiments.

• Neuropharmacological Research
  It serves as a reliable agent for studying chronic GABAergic modulation, including anxiolytic, anticonvulsant, and sedative effects over time in laboratory animals.

• Pharmacokinetic Modeling
  Its slow metabolism and long duration support extended monitoring in pharmacokinetic trials, useful for modeling plasma-level curves and receptor interaction timelines.

• Forensic and Toxicology Studies
  Due to its detectability over prolonged periods, it is often included in toxicology screens and post-mortem evaluations to assess long-term benzodiazepine exposure.

• Comparative Benzodiazepine Studies
  N-Desalkylflurazepam is commonly used as a control substance in side-by-side experiments assessing the differences between long- and short-acting benzodiazepine derivatives.

The legality of N-Desalkylflurazepam is highly dependent on regional, national, and institutional regulations. While not scheduled under many international drug conventions, it may be regulated under analogue or psychoactive substance laws in certain countries.

• Not Scheduled Internationally
  N-Desalkylflurazepam is not classified under the UN’s controlled substances list, which allows it to be legally imported or exported for research in many jurisdictions.

• Controlled Under Analogue Laws in Some Regions
  In countries like the United States or Australia, it may fall under analogue legislation due to its structural similarity to regulated benzodiazepines, making possession or sale without authorization potentially illegal.

• Not Intended for Human Consumption
  This compound is strictly marketed for laboratory and forensic research purposes. We at RC Plug provide clear labeling to avoid misuse and ensure compliance with laws pertaining to chemical handling.

• Researcher Responsibility
  It is the buyer’s responsibility to ensure that the acquisition and use of N-Desalkylflurazepam complies with local, state, or national regulations.

• Customs Documentation Support
  RC Plug offers discreet and compliant documentation upon request to support smooth customs clearance, especially for academic and licensed institutions.

Proper storage of N-Desalkylflurazepam is essential to preserve its chemical integrity, avoid degradation, and ensure consistent research outcomes. Failure to store the compound under optimal conditions may lead to structural changes, reduced potency, or contamination.

• Temperature Range: 4°C to 8°C
  Refrigerated storage is ideal. Storing it in a temperature-controlled environment helps maintain chemical stability, especially for long-term projects.

• Avoid Light Exposure
  The compound should be kept in opaque containers to prevent light-induced degradation. UV and visible light can impact benzodiazepine ring stability.

• Use Moisture-Proof Packaging
  We ship the product in vacuum-sealed bags with desiccants to prevent hygroscopic absorption, which could cause clumping or hydrolysis.

• Minimize Air Exposure
  Each time the container is opened, exposure to oxygen can slowly oxidize the compound. Use inert atmosphere storage (like nitrogen flushing) if repeated access is necessary.

• Keep Away from Reactive Substances
  Store separately from oxidizers, acids, and solvents to prevent contamination or unwanted reactions.

• Do Not Freeze
  Freezing can cause microcrystal formation and irreversible structural damage in some compounds. Always refrigerate, not freeze.

N-Desalkylflurazepam distinguishes itself from other benzodiazepines due to its direct pharmacological activity, metabolic resilience, and extended half-life. While many benzodiazepines are administered as prodrugs and undergo hepatic transformation to become active, N-Desalkylflurazepam is immediately active, which makes it valuable for precision-focused studies in receptor pharmacology and CNS modulation.

• Directly Active Compound
  It is not a prodrug. Its activity is not reliant on enzymatic conversion, which removes the variability of hepatic metabolism and enables predictable pharmacokinetics in lab models.

• Exceptionally Long Half-Life
  With a duration exceeding 100 hours in some studies, this compound allows for long-term observation of receptor binding and effect profiles without repeated dosing, which is uncommon among most benzodiazepines.

• High Lipid Solubility
  Its lipophilic structure allows rapid penetration across the blood-brain barrier, making it suitable for central nervous system studies without lag in onset.

• Stable Under Laboratory Conditions
  Unlike many benzodiazepines that degrade quickly or form inactive metabolites, N-Desalkylflurazepam retains stability in solution and powder form, even during prolonged experiments.

• No Accumulation of Active Metabolites
  This compound does not break down into other active forms. This is advantageous in minimizing off-target effects and simplifying data interpretation in repeated-dose studies.

N-Desalkylflurazepam is well-known in the research community for its remarkably extended duration of action. This is one of its core characteristics and a major reason for its popularity in long-term receptor-binding studies, behavioral monitoring, and chronic dosing models.

• Sustained CNS Binding
  Once administered, the compound remains bound to GABA-A receptors over several days, resulting in continuous GABAergic enhancement, especially in rodent models.

• Effect Duration of 72 to 96 Hours
  In vivo studies have shown functional effects—such as sedation, anxiolysis, and muscle relaxation—persisting for up to four days with a single administration.

• Minimal Fluctuation in Plasma Levels
  Plasma concentrations remain stable, contributing to clean pharmacokinetic curves that simplify interpretation and modeling.

• Ideal for Chronic Exposure Studies
  The prolonged effect allows researchers to simulate extended therapeutic exposure without repeated dosing, lowering the risk of experimental confounds.

• Low Inter-Subject Variability
  Because of its metabolic stability and minimal breakdown, variability in results across lab subjects tends to be lower, making findings more reproducible.

Depending on the nature of the research—whether it’s in vitro receptor binding or in vivo behavioral studies—N-Desalkylflurazepam is typically administered in carefully prepared solvent systems. The compound’s solubility characteristics require proper solvent selection to ensure complete dissolution and bioavailability in research settings.

• In Vitro Use (e.g., Binding Assays)
  Typically dissolved in DMSO, ethanol, or methanol for use in receptor-binding assays or chemical interaction studies at micro- to nanomolar concentrations.

• In Vivo Use (e.g., Animal Studies)
  Often prepared in PEG-400 or ethanol diluted with saline for administration via oral gavage or injection. Careful dilution ensures proper distribution and avoids precipitation.

• Solubility Considerations
  The compound is not water-soluble; therefore, co-solvents must be used. Ethanol-based solutions are common, but researchers must avoid using too high a concentration to prevent toxicity.

• Sterility Requirements
  When used in animal studies, solutions must be sterilized through filtration (typically 0.22 µm filters) and prepared in sterile conditions to prevent infection or contamination.

• Controlled Dosing Protocols
  Because of its long duration, small doses are often sufficient. Frequent dosing is discouraged to avoid cumulative CNS depression in animal subjects.

Like all benzodiazepine analogues, N-Desalkylflurazepam must be handled with extreme care in a research setting. Although it is not scheduled in many countries, it remains a potent CNS depressant, and exposure without protection can pose significant risks to lab personnel.

• Risk of Accidental Inhalation or Ingestion
  In powdered form, it may become airborne and be accidentally inhaled. Accidental exposure can lead to sedation, dizziness, or respiratory depression in humans.

• Skin Absorption Hazards
  Benzodiazepines can be absorbed through the skin. Gloves must be worn during all handling procedures, particularly when weighing or preparing solutions.

• Central Nervous System Effects
  Exposure, especially through skin or mucous membranes, may lead to acute CNS depression, including drowsiness, slowed reflexes, and confusion.

• Potential Legal Consequences
  Unauthorized handling or possession without a clear research purpose may result in legal scrutiny, particularly in regions with strict analogue laws.

• Contamination Risk
  If mishandled, it could contaminate lab equipment or other research compounds, potentially compromising other experimental work.

Yes, N-Desalkylflurazepam readily crosses the blood-brain barrier (BBB), which is one of the primary reasons it is widely used in CNS-targeted research. Its physicochemical properties—including molecular weight, lipophilicity, and structural simplicity—facilitate efficient passage through the BBB.

• High Lipophilicity Enhances CNS Penetration
  Its structure includes halogenated aromatic rings that significantly increase lipid solubility, a key factor for BBB permeability.

• Rapid Onset in Rodent Models
  When administered systemically, effects begin to appear quickly due to its swift transit across the BBB, enabling time-sensitive behavioral testing.

• Useful for CNS Receptor Studies
  Its ability to reach central GABA-A receptors in brain tissues allows precise analysis of binding kinetics, receptor occupancy, and downstream signaling.

• Predictable Distribution Profile
  In both small animal and primate models, the distribution follows a consistent pattern of accumulation in brain regions rich in GABA-A receptors, such as the cortex and hippocampus.

• Supports Behavioral and Cognitive Analysis
  Because it reaches the CNS efficiently, it’s ideal for experiments measuring sedative, anxiolytic, or memory-altering effects.

N-Desalkylflurazepam and Diazepam are both benzodiazepine-class compounds that act as positive allosteric modulators of the GABA-A receptor. However, N-Desalkylflurazepam exhibits a significantly different pharmacodynamic and pharmacokinetic profile, particularly in binding affinity, receptor selectivity, and duration of action. These differences are highly relevant for researchers looking to study long-term GABAergic modulation.

• Higher Affinity for Certain GABA-A Subtypes
  Studies suggest N-Desalkylflurazepam may have a slightly higher affinity for α1, α2, and α3 subunits of GABA-A receptors compared to Diazepam, allowing for more selective receptor interaction in controlled models.

• Longer Receptor Occupancy
  Due to its extended half-life, it remains bound to GABA-A receptors much longer than Diazepam, which contributes to a prolonged modulatory effect in vitro and in vivo.

• Reduced Off-Target Activity
  Compared to Diazepam, which has some affinity for peripheral benzodiazepine receptors and other CNS targets, N-Desalkylflurazepam tends to show cleaner receptor targeting, especially in radioligand binding assays.

• More Stable Plasma Levels
  N-Desalkylflurazepam avoids the trough-peak fluctuations often seen with Diazepam, creating a more stable experimental environment over several days of observation.

• Minimized Active Metabolite Interference
  Unlike Diazepam, which converts into several pharmacologically active metabolites (e.g., desmethyldiazepam, temazepam), N-Desalkylflurazepam has no known significant active metabolites, offering clearer results in dose-response studies.

Yes, RC Plug prioritizes strict quality control and lab validation for every compound, including N-Desalkylflurazepam. Purity testing is critical in scientific research to ensure results are not skewed by impurities or unidentified by-products. We implement a robust, multi-stage testing protocol before any product is released for sale.

• Third-Party Lab Testing
  All our batches are sent to ISO-accredited third-party labs for GC-MS (Gas Chromatography–Mass Spectrometry) and HPLC (High-Performance Liquid Chromatography) testing.

• Purity Verified ≥99.5%
  Each lot of N-Desalkylflurazepam meets or exceeds 99.5% purity standards, ensuring optimal integrity and reproducibility in research applications.

• Full Certificate of Analysis (COA)
  Upon request, we provide a batch-specific COA including chromatogram data, impurity profiling, and testing conditions.

• Cross-Test Verification
  Whenever possible, compounds are tested with two or more methods (e.g., GC-MS and NMR) to cross-verify identity and structural purity.

• Residual Solvent and Moisture Testing
  Our testing process also includes checks for moisture content and residual solvents that could affect solubility or stability.

N-Desalkylflurazepam is moderately hydrophobic, meaning it requires organic or semi-organic solvents to achieve full solubility. Choosing the appropriate solvent is crucial to maintain the compound’s chemical integrity and effectiveness in research experiments.

• Ethanol
  Ethanol is one of the most common solvents used for dissolving N-Desalkylflurazepam due to its compatibility with both in vitro and in vivo research. It offers relatively fast dissolution and is easily diluted in physiological buffers.

• DMSO (Dimethyl Sulfoxide)
  A high-grade DMSO solution is ideal for receptor-binding studies and biochemical assays. It provides complete dissolution at low volumes, but concentrations must be controlled to avoid cytotoxicity.

• PEG-400 (Polyethylene Glycol)
  Frequently used in in vivo studies for oral or parenteral administration. PEG-400 enhances solubility while minimizing precipitation upon dilution with saline.

• Methanol (For Analytical Use Only)
  Used primarily in analytical chemistry applications such as chromatography or spectroscopy; not typically suitable for biological assays.

• Avoid Water Alone
  The compound is virtually insoluble in pure water and may precipitate or aggregate, reducing its effectiveness and complicating dosing protocols.

N-Desalkylflurazepam is known for its chemical stability under proper storage conditions, making it suitable for long-term research projects. The compound retains its pharmacological and structural integrity when stored as instructed.

• Shelf Life: 24 Months Minimum
  Under refrigerated and moisture-controlled conditions, the compound remains stable and retains its potency for at least two years.

• Vacuum-Sealed Packaging Enhances Longevity
  All shipments from RC Plug are vacuum-sealed and include moisture-absorbing agents to maintain the ideal chemical environment.

• Temperature Sensitivity
  Temperatures above room level may accelerate degradation, especially when combined with light and moisture exposure. Avoid storage near heat sources or in high-humidity areas.

• Stability in Solution
  Once dissolved, solutions of N-Desalkylflurazepam should be used within 2–7 days and kept refrigerated. For extended use, freezing aliquots is discouraged due to possible crystallization or precipitation.

• Integrity Testing
  We recommend checking for discoloration, clumping, or changes in solubility after prolonged storage to confirm the compound remains intact.

Yes, oral activity has been consistently observed in preclinical models using N-Desalkylflurazepam. Its lipophilic nature allows it to be absorbed efficiently through the gastrointestinal tract, making it suitable for oral administration in rodent or non-human primate studies.

• High Oral Bioavailability
  The compound demonstrates significant absorption when administered orally, with studies reporting near-complete systemic availability in animal models.

• Delayed but Prolonged Onset
  Compared to intravenous or intraperitoneal administration, oral ingestion may delay the onset of action slightly, but it extends the effect profile due to slow systemic clearance.

• Ideal for Chronic Dosing Protocols
  Its long duration and consistent absorption allow researchers to use once-daily or even once-every-2-day dosing strategies in chronic exposure models.

• Minimal First-Pass Metabolism
  Unlike many oral benzodiazepines, N-Desalkylflurazepam does not undergo extensive hepatic transformation, reducing inter-subject variability.

• Formulation with PEG or Ethanol
  In research settings, oral solutions are often prepared in PEG-400 or ethanol-based carriers for stability and ease of administration.

N-Desalkylflurazepam is particularly well-suited for chronic research protocols due to its long half-life, sustained receptor activity, and non-sedative profile at controlled doses. Its pharmacological characteristics make it ideal for long-duration studies, particularly those focusing on tolerance, receptor modulation, or long-term behavioral changes.

• Extended Activity Supports Long-Term Observation
  With a half-life exceeding 100 hours, the compound supports prolonged receptor occupancy, reducing the need for repeated administration in chronic dosing schedules.

• Stable Plasma Concentrations
  Research shows minimal fluctuation in blood concentration levels over time, making it useful for studies requiring steady-state conditions.

• Low Risk of Tolerance in Short-Term Models
  Short- to mid-duration studies report minimal tolerance development, which is essential in examining baseline receptor sensitivity without confounding effects.

• Supports Receptor Downregulation Analysis
  Because of its persistent activity, it is a valuable tool in analyzing receptor desensitization and downregulation pathways over time.

• Reduced Animal Stress
  The ability to administer infrequent doses helps minimize handling stress in animal models, improving the accuracy of behavioral assays.